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Abstract

Breast cancer is the most common cancer seen in women worldwide
accounting for more than 1 .3 million cases and 458 000 deaths a year worldwide.
Breast cancer patients are at high risk of recurrence in the form of metastatic
disease. Genes associated with invasion and metastasis provides an aggressive edge
in proliferation and growth during colonization of the metastatic site. The
SMARCAD 1 (SWIIS F-related, Matrix-associated Actin-dependent Regulator of
Chromatin, containing DEADIH box I ) protein is the human homolog of yeast
Fun30 (Function Unknown Now 30) proteins. These proteins are members of the
Snf2 helicase motif-containing protein families, and are known to act as ATP
dependent D A translocators. Previous studies have shown that yeast Fun30
deletions are resistant to ultraviolet (UY) radiation. The over-expression of Fun30
has been shown to affect chromosome stability , integrity , and segregation. Fun30
has also been shown to be a potential cyclin-dependent kinase (Cdk l )/Cdc28
substrate. The SMARCAD 1 is a DEADIH box-containing helicase which includes
proteins essential for repl ication, repair, and transcription. In addition to two
DEADIH box and an ATP-binding motifs within SMARCAD l , it has a putative
nuclear localization signal and several regions that may mediate protein-protein
interactions. Expression analysis indicates that SMARCAD 1 transcripts are
ubiquitous, with particularly high levels in endocrine tissue. The gene for
SMARCAD 1 has been mapped to the chromosome 4q22-q23m, a region rich in
break points and deletion mutants of genes involved in several human diseases,
notably soft tissue leiomyosarcoma, hepatocellular carcinoma, and hematologic
malignancies. It has been recently reported that the binding sites of endogenous
SMARCAD 1 IKIAA I 1 22 are frequently found in the vicinity of transcriptional start
sites. Moreover, human SMARCAD I overexpression was observed in E I A
expressing cell l ine with increased capacity for gene reactivation events by genomic
rearrangements suggesting that human SMARCAD 1 may play a role in genetic
instability . Previous studies in our laboratory showed that the breast cancer cells
estrogen receptors (ER)-negative M DA-MB-23 1 and MDA-MB-23 1 - 1 83 3 as well
as ER-positive MCF-7 and T47D express a high level of SMARCAD I in
comparison with the nonnal breast epithelial cells NHME.
In my master research proj ect, we investigated the impact of specific
silencing of S MARCAD I on human breast cancer cell proliferation, colony growth,
morphology , migration and invasion using human breast cancer cells estrogen
receptors (ER)-negative M DA-MB-23 I .
In this respect, the cells were stably transfected with two different designs
of SMARTvector 2.0 Lentiviral shRNA particles targeting SMARCAD l . Control
cells were transfected with SMARTvector 2.0 Non-Targeting control particles.
The positive c lones ( 1 0 to 1 2 from each design) were selected under puromycin
and the GFP positive c lones were analyzed using western-blot to confirm specific
SMARCAD I silencing. The two different design of shRNA targeting
S MARCAD I induced 99% decreased in the SMARCAD 1 protein level
(SMARCAD 1 -shRNA l , and SMARCAD l -shRNA3). The selectivity of this
silencing was confirmed by the fact that no impact on SMARCAD I protein was
observed in the cells transfected with shRNA-conh'ol particles (control-shRNA).
We demonstrated for the first time that silencing of SMARCAD I resulted in a
xi

significant inhibition of cellular proliferation and colonies formation in soft agar,
as well as cellular migration, and invasi eness. All together, these results strongly
suggest that SMARCAD 1 may play an important role in breast cancer growth and
metastasis.
Identi fication of new molecular effectors and signaling pathways involved
in breast cancer growth, invasion, and metastasi s could lead to effective targeted
approaches in breast cancer therapy .

xii

Table of Contents
Dedication

.

ACKNOWLEDGMENTS
Abstract

2.

Breast Cancer Epidemiology

2.2.

UAE

xi

............................................................................................................

1

.....

2

.

............... · . . · .................. ............................................... ....

2

.

.

2

...................... ........... . . . ................................................ ............................

.

.................................. ........................................................................................

Breast Cancer Risk Factors
Hormonal factors

3.2.

Dietary factors

3.3.

Lifestyle and Environmental factors

3.4.

Genetic risk factors

...

.

2

............................................................................................

3.1.

4.

.........

.

Breast Cancer

WorJdwide

ix

................. ........................................................................................

1.

2.1.

..

...................................... .................... ........................................

........................................................................................................................

Chapter 1: Introduction

3.

iii

.

....... ............................... ....................... ..... ...............................
......................... .

3

.

.................... ................... .................................... .......................

.

.............................................. ....... .... . . ................................. ...............

..........................................................................

......................... . . . . . . ............................. ........................................

.

Types of breast cancer

............................. ......................................................................

4.1.

Ductal carcinoma in situ DCIS

4.2.

Infiltrating breast cancer.

4.3.

Inflammatory breast cancer IBC

.

5.

Breast cancer stages

.

6.

Breast cancer invasion and metastasis

7.

Pathogenesis o f breast cancer: key genes and pathways

................................................... .................................................

7.2.

Non-hormonal factors (p53)

.

.... .....

8.

Diagnosis

9.

Current therapeutic approaches

.

13
14

..............

15
15

..........................................................................

......................................................................................................................

.

.

........ ...... ........ .......................

9.1.

Chemotherapy

9.2.

HormonallEndocrine Therapy

9.3.

HER-2 Receptor Targeted Therapy

10.

Aims of the Research .

.

.

17
18

.

.... ...... ........................

18

.

................................ . . . . . . . . ................. . . ............. .................................

..................................................................................

21
22

.........................................................................

23

.. ............................................................................................

Chapter 2 : Materials & Methods
2.1 Cell culture and reagents

........ ................ . . .

.. .
. .

..........................................................

26

.

.............. ..... ................... ......................... ................................

2.2 Establishment o f Stable SMARCAD1 silencing in breast cancer cells

. ........................

2.4 Cell proliferation assay

.

...... ...........................................................................................

2.5 Soft-agar colony formation assay

..................................................................................

xiii

9

12

...................................... . .......

Hormones and tyrosine kinase receptors (estrogen and HER-2 receptors)

7

12

............................................ .............................

7.1.

7

12

.................... ...................................... ............. .................

.

6

11

. ........................................................ .......................

. ..... ............ ...........................................................

5

27
27
28
29

2.6 Cellular Morphology

......................................................................................................

2.7 Wou nd bealing motility assay
2.8 Matrigel invasion assay

........................................................................................

Chapter 3: Results

30

...... ............................................................................................

2.9 The Oris™ Collagen I Cell Invasion Assay
2.10 Cellular viability

30

31
31

...................................................................

................................. . . .......................................................................

32

...... . . .............. ............................................................... . . . . . ......................

3.1 Human Breast Cancer Cell Line Over-express SMARCADl..

....................................

33
34

3.2 SMARCADI silencing decreased MDA-MB-231 cell proliferation and colonies growth
in soft agar

............................................................................................................................

37

3.3 SMARCAD1 silencing impairs breast cancer cell migration and invasion

. ..................

39

3.4 Impact of SMARCADI silencing on the anti-cancer effect of paclitaxel and Frondoside
A in

vitro. ............................................................................................................................ .43

Chapter 4: Discussion
Chapter 5: References

.............. . . ..........................................................................................

..................................................................................................... . ....

xiv

44
55

Chapter 1
Introduction

1

1.

Brea t Cancer

Breast cancer is a tumor that forms in the mammary glands, most commonly
from the inner lining of milk ducts or the lobules. It can affect both male and
female; however, breast cancer in male, is rare.

2.

B reast Cancer E p idemi ology

2.1.

Worldwide

Breast cancer is the second most common cancer in the world after lung
cancer. It is however, the most common cancer worldwide in women with 1 .38
million cases of breast cancer (23% of total cancer burden) in 2008. Breast cancer
is the fifth cause of death from cancer overall (45 8 000 deaths), but it is still the
most frequent cause of cancer death among women worldwide [ 1 ] , [2]. One in nine
women is estimated to develop breast cancer in her lifetime, and I in 29 is
expected to die from it [ 3 ] . About 50% of the breast cancer cases and 60% of the
deaths are expected to occur in developing countries. Western countries have the
highest incidence rates, but lowest death rates. Some of the factors that added to
the international variations in the incidence rates are largely the differences in
reproductive and hormonal issues and the accessibility of early detection services.
Recent use of postmenopausal hormone therapy or late age at first birth are
considered reproductive factors that increase the risk of breast cancer. Alcohol
consumption also increases the risk of breast cancer [2] .

2.2.

UAE

Cancer

IS

the third leading cause of death i n the UAE following

cardiovascular diseases and accidents. Data from the UAE M inistry of Health
point out that cancer accounts for approximately 500 deaths per y ear. Increasing
2

numbers of young women being detected with breast cancer, debunking earlier
findings that women above 45 were more prone to the disease, according to
HAAD's breast cancer awareness team. Breast cancer accounts for 28 per cent of
all female deaths in the UAE. Previously women in their 40s and above were
affected [4 ] . Unfortunately, over the past few years an increasing number of
women in their early 30s and 20s were diagnosed with breast cancer due to the
adoption of a Western lifestyle -- which primarily manifests itself in an increased
intake of high-calorie food -- and lack of awareness on how to seek early
treatment. Statistics show that 1 60 women develop breast cancer every year in Abu
Dhabi alone. Breast cancer occurrence rates are very low among women below the
age of 25 . After this age, the incidence rate stads to rise. For example, roughly
about one quad er of the breast cancers occur in the age group of 25 to 49 years,
one quader in women of 50 to 59 years of age, and the incidence peaks in women
over 60 years of age - almost half of the cases fal l into this age category. Even
though the number of cases is increasing, the overall modality due to breast cancer
has decreased. Mostly, this is attributed to early detection and advanced treatment
possibilities [3].

3.

B reast Ca ncer Risk Factors

With regards to breast cancer, every woman is at risk of developing this
disease. However, knowing the risk factors doesn't tell us evelything. This does not
mean that a female will get the disease by having a risk factor, or even several risk
factors. Most women who have one or more breast cancer risk factors never
develop the disease, while many women with breast cancer have no obvious risk
factors (other than being a woman and growing older).
3

The most well recognized risk factors for breast cancer are age and family
history. The ri k of developing breast cancer increases by getting older and can be
doubled every ten years, and at the age 70 breast cancer incidence can reach to 500
cases per 1 00,000 women [5] .

About 1 out of 8 invasive breast cancers is

established in women younger than 45 , whereas about two out of three invasive
breast cancers are found in women at age 55 or older [6] . However, young women
diagnosed with breast cancer have more aggressive tumors associated with poor
surv ival prognosis [7]

.

The main risk factor for developing breast cancer is simply being a woman.
Gender is by far the most important risk factor. Breast cancer occurs 1 00 times
more regularly in women than men [8]. The main reason why women develop more
breast cancer is that women ' s breast cells are regularly exposed to the growth
promoting effects of the female honnones estrogen and progesterone [9] .

4

Increase hormonal exposure in early menarche and late menopause is also
considered as a ri sk factor. Early exposure to ionizing radiation, alcohol
consumption, high breast density and some medications such as long-term
postmenopausal honnone, like estrogen replacement are sti l l controversial risk
factor for breast cancer [ 1 0].

3.1.

Hormonal factor
In postmenopausal women, elevated levels of some honnones, like estrogen

and androgen, are associated wi th increased risk of breast cancer [ 1 1 ) . Females that
have early menarche or late menopause have more menstrual cycles and thi s leads
to longer exposure to estrogen and consequently to increase the ri sk of developing
breast cancer. So any sti mulus that leads to increase in exposure to these hormones
is considered as a ri sk factor for breast cancer.
It has also been reported that women taking postmenopausal hormonal
replacement therapy for five years or more have a high ri sk of developi ng breast
cancer [ 1 2, 1 3) . Several epidemiological and ani mal studies suggest that l 7�
estradiol ( E2) is directly involved in breast cancer

via

an unknown mechani sm.

Two pathways are i nvolved in estrogen carcinogenesi s: E2 metabolism and E2
estrogen receptor. 2-0H and 4 -0H catechol estrogens are two metabolites of E2
that develop

via

phase I metabolism and oxidation. These metabolites cause DNA

damage leading to cancer. In addi tion,

via

proli feration and gene expression [ 14) .

5

estrogen receptors, E2 can sti mulate cell

3.2.

Dieta ry factors

Several studies suggests an association between sunlight exposure and low
breast cancer occurrence and mortality [ 15 ] . Vitamin D, which comes as a result of
exposure to the sunlight has anti carcinogenic properties ( 1 6) . The biologically
active form of vitamin D, the 1 ,25(OH)2D, has anti-proliferative and pro-apoptotic
effects and promotes the differentiation of breast cancer cells [ 15 ] . However,
females with very dense breast tissue are at high risk of subsequent breast cancer
[ 15 ] .
Additionally, being obese increases the risk for developing breast cancer by
30 to 5 0%. POlter and his colleagues revealed that obese patients show larger, more
advanced, and aggressive tumors [ 1 7] . This might be due to the increases in the
production of estrogen through the activity of aromatase in breast adipose tissue
[ 1 8] . The increases in breast cancer risk and mortality have been mainly associated
with the upper body obesity as defmed by the waist-to-hip ratio [ 1 9] . Increased
estrogen production in obese patients is associated with the increased risk of breast
cancer and enhanced progression of ER + breast cancer [20] . Physical activity
during adolescence may be particularly protective. However, minor differences
were observed between physically active premenopausal women and sedentary
women [2 1 ] .

6

3.3.

Lifesty l e a n d En viron mental factors

Smoking and alcohol consumption are also considered as risk factors. The
growth of breast cancer cells could be enhanced by nicotine, which means that
nicotine can be transported to the breast tissue via plasma lipoproteins following its
passage through the alveolar membrane, and directly contribute to the molecular
mechanism of brea t carcinogenesis [22]. Comparing smokers to women who have
never smoked or are not currently smoking but whose passive smoking exposure
was unknown, the risk of breast cancer increased among the women who smoke
cigarettes [23]. However, another study showed little or no association [24 ] .
Women who are exposed to high doses o f radiation, mostly through
adolescence, have an increased risk of breast cancer. This l ink has been noticed
among women who received high-dose radiation for medical purposes [25 ] .
Uncertainties remain about the effects o f low dose chest X-rays, particularly in
individuals at increased genetic risk.

3.4.

Genetic risk factors

Cancer is caused by either alterations in oncogenes, tumor-suppressor
genes, and/or microRNA genes [26] . Around 5 to 1 0% of breast cancer cases are
thought to be inherited resulting directly from gene defects (called mutations)
inherited from a parent. The risk of breast cancer is increased two- to three-fold in
female with a family history of breast cancer [27].

7

BRCAI and BRCA2: In normal circumstances, expression of these genes helps to

avoid cancer and prevent the cells f rom growing abnormally. Deletions and
inactivating point mutations in these two genes cause a significant increase in the
risk of developing breast cancer [28] [29], [6] . BRCA I is located on chromosome
1 7 and play a role in many cellular process such as maintaining genome integrity
DNA repair and tumor transcriptional regulation and suppression. The percentage
of women who develop breast cancer with mutation of BRCA I is between 50-80%
[30] . BRCA2 is located on chromosome 1 3 and it is responsible for preventing cells
from uncontrolled proliferation and in repairing DNA damage. The risk of breast
cancer in mutated BRCA2 is about 60-80% [27] . Family history of breast cancer is
a well-known risk f actor for breast cancer; the risk can increase in flfst-degree
relatives with an average of about twofold [3 1 ] . In young women carrying gremlin
mutations in

BRCAl

and

BRCA2,

breast cancer is likely to occur and often affects

both breasts. Generally, tumors with

BRCAI

mutations are negative for estrogen

and progesterone receptors. However, most

BRCA2

mutations are positive for these

hormone receptors. Cells with mutations in

BRCAI

or

BRCA2

gene lack functional

BRCA I or B RCA2 protein and have a decreased ability to repair damaged DNA
and grow in an uncontrolled manner [32].

8

PS3 tu mor

u p p re sor gene: the flrst tumor suppressor gene identified was the

p53 gene [ 3 3 ] . This gene is localized on the short

arm

of chromosome 1 7 and it

encodes a 393 -amino acid protein, which is expressed at very low Ie els in normal
cells [34] . P53 remains the most frequently mutated gene in human cancers, about
50% of people with cancer have their P53 gene mutated, with an overall frequency
of 25% in breast cancer patients [33], [3 5 ] . The most aggressive forms of breast
cancer have P53 mutations, which are remarkably frequent, and apparently among
the key driving factors [36]. The functions of p53 in normal circumstances are to
inhibit the proliferation of abnormal cells, thus preventing neoplastic development.
Activation of p53 signaling pathway, which used to be on ' standby' mode under
normal cellular conditions, take place in response to cellular stresses, and several
anticancer agents. The L i-Fraumeni syndrome can be caused by inherited mutations
of the p53 and people with this syndrome have an increased risk of developing
breast cancer, as well as several other cancers [29] .
H E R-2: The tyrosine kinase receptor HER-2 gene mediates critical signaling

functions in normal and malignant breast epithelial cells. Approximately 20 to 25%
of humans have an overexpression of HER-2 receptor, which can lead to breast
cancer [ 3 7) . An aggressive clinical phenotype of breast cancer is related to
overexpression of HER-2 that includes high-grade tumors, increased growth rates,
early systemic metastasis, and decreased rates of overall survival. This HER-2
overexpression can result in changes in the biological features of breast cancer,
including increased proliferation and motility, suppression of apoptosis, higher
invasive and metastatic behavior, and independence of steroid hormones [37).

9

4.

Type of breast c a n c e r

The female mammary glands have a role i n both nourishing the offspring as
well as offering irnmunologjcal protection to the newborn baby. Each breast ha 15
to 2 0 lobes; each lobe has many smaller lobules which end in dozens of little bulbs
that can produce milk. Thin tubes called ducts are linked to lobes and lobules and
eventually lead to the main lactiferous ducts, which open in the nipple (Schema 1 ).
Fat, blood and lymphatic vessels occurring in each breast fil l the spaces between
the ducts and secretory units. The lymph vessels lead to small bean-shaped organs
called lymph nodes, clusters of which are found in the axilla and in many other
regions of the body.
Thoracic branch of
auDlia�' arte�-

.-\dip ose rissue

_-\reola
::'.lppJe

_-\mpolla

Subcutaneous fat of the
breast

Schema 1: Anatomy of the breast
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Breast cancer can be classifi ed into two types (ductal and lobular cancer) according
to the structure of the breast affected by cancer. The most common type of breast
cancer is ductal carcinoma (7 of every 1 0 women) followed by lobular carcinoma
( 1 of every 1 0 women).
Breast cancer is also classified according to its invasive status. If the cancer is
judged to be non-invasive, it is called

"in situ",

referred to as "infi ltrating" . The term

"in situ"

and the invasive breast cancers are

is defined as the cancer that has not

spread into tissue other than the one it started in [38].
4.1.

D u ctal carcinoma in situ DCIS.

DCIS is a non-invasive breast cancer characterized by early-stage cell
abnormal ities in the breast ducts. If it is untreated, about 30-50% of DCIS progress
to a more invasive types of cancer [39]. Before 1 980, DCIS was rarely diagnosed,
but now about 25 % of DCIS are diagnosed in the United States due to the progress
in the diagnostic methods. DCIS can be classified according to phenotypic pattern
of the cells (solid, cribriform, papillary, and micro-papillary), tumor grade (high,
intermediate, and low grade), and the presence or absence of granulomatous
mastitis [40] . Breast cancer deaths linked with DCIS are due to the subsequent
development of invasive carcinoma or areas of invasion that were left undetected at
the time of diagnosis. However, when properly treated, DCIS are cured. On the
contrary, at least half of invasive carcinomas have developed metastasis at the time
of diagnosis [8].
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4.2.

I nfIltra ti ng or i n va i e b reast can cer.

This is an aggressive type of breast cancer, which metastasizes to different
organs such as lungs and bones.

4.3.

I nfla mmato ry b reast can cer ( I BC).
mc has a poor prognosis and presents with symptoms resembling an

inflammation. The cancerous cell emboli block the lymph vessels, leading to rapid
swelling of the breast, skin thickness and nipple retraction with redness and
persistent itching [4 1 ] . In the United States, I BC represent up to 6% of breast
cancer patients [42]. The 3-year survival rate for patients with mc was far lower
(34%) than that for patients with other types of breast cancer (90%) [43] .

Stage Grading
0
I
l IA

lID
IlIA

IIIB

I I Ie
IV

Tis
T1*
TO
Tl*
T2
T2
T3
TO
T1 *
T2
T3
T3
T4
T4
T4
Any T
Any T

NO
NO
Nl
Nl
NO
Nl
NO
N2
N2
N2
Nl
N2
NO
Nl
N2
N3
Any N

MO
MO
MO
MO
MO
MO
MO
MO
MO
MO
MO
MO
MO
MO
MO
MO
Ml

Table 1 : New TNM staging classification approved by
AJCC [44]
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5.

B rea t cancer tage

In order for the oncologist to design a treatment regimen for patient

cancer

taging I Important. In 2000 a breast cancer ta k force wa constituted to ad Ice
Amencan Joint Committee on cancer to receive the sixth edition of cancer staging
manual [44 ] . With the new achievement in diagnosis and treatments in the field of
brea t cancer, change were needed in the TNM- taging sy tem (Table 1 ). The
tage of breast cancer depends on the size of the brea t tumor and whether it has
pread to lymph nodes or other parts of the body. T ref ers to the primary tumor, N
to the lymph nodes and M to the existence or ab ence of metastasis in other organs
of the body.
tage 0: ref ers to the non-in asive breast cancer in which cancer cells have not

spread into neighboring breast tissue or outside the duct in case of DCIS or outside
lobule in the case of lobular carcinoma

in situ.

Stage I : the breast tumor is no more than 2 cm in diameter and the cancer cells

have not spread to the lymph nodes
Stage I I : is divided into two subcategories I IA and lIB
Stage I I A : the tumor is no more than 2 cm in diameter and has spread to the

auxiliary lymph nodes, or the tumor is between 2-5 cm in diameter and has not
spread to the lymph nodes.
Stage lI B : the tumor is between 2 and 5 cm in diameter and has spread into the

auxiliary lymph nodes or larger than 5 cm in diameter and has not spread to lymph
nodes.
Stage I I I: is subdivided into three categories:
Stage IlIA occur in two main scenarios:
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I . The tumor is no larger than 5 cm in diameter but ha spread to auxiliary
lymph node

that grow together fomllng clumps. The cancer may also

pread mto the cervical lymph nodes.
2. The tumor i larger than 5 cm in diameter and the auxiliary lymph nodes do
not adhere to each other or other tis ues.
tage I I I B: the tumor can be of any size and it spread to the skin of the breast or

chest wall. This stage may also include swelling of the breast and lwnps in the skin
of the breast

0

inf lammatory breast cancer is considered at least stage l II B .

tage I I IC: the tumor can b e of any size but i t spreads t o the lymph nodes area

above or below the cla icle , chest wall and indoor the skin of breast.
tage IV: it is known as distant metastatic cancer, the last stage of breast cancer,

the tumor can be of any size and cancer cells have spread to other parts of the
body, such as the lungs, liver, bones, or brain. The 5year survival rate is 1 3% [8].

6.

B reast cancer in va ion and meta tasis

Metastasis is a complex process, starting from the migration and invasion of
cancer cells into the nearby tissues and lymphatic circulation. To form new colonies
at metastatic sites, breast cancer cells must have access to the circulatory system
and proliferate in vital organs, such as lungs, bones, brain and l iver. In order to
promote these steps of motility and invasion, the tumor microenvironment has an
essential role by either secretion of chemotactic f actors, such as (chemokines,
growth factors, and matrix metalloproteases, which are felt by cancer cell surface
receptors including integrins, receptor tyrosine kinases and G protein-coupled
receptors (GPCRs)) or by direct interactions with stromal cells [45 ] .
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el lular motility.' in asion in three-dimen ional extracellular matrix (ECM )
can b e explamed by the lamellipodium exten ion a t the leading edge. This can lead
to the formation of new focal adhe ions comple e

secretion of urface protease

in contact with ECM and focal proteoly is. The cell body contraction by
actomyosin complexe

will end up by cytoplasmic tail detachment and cell

movement. Brea t cancer cells re pond to chemotactic signals by reformation of
their cytoskeleton through Rho family of small GTPases members Rho, Rac, and
Cdc42. Rho controls the stress fibers and focal adhesion formation, Rac regulates
membrane ruffl ing and lamellipodia and Cdc42 regulates fi lopodia formation [45 ] .

7.

Pathogene is of b reast cancer: key genes and pathways

Familial breast cancer involved two human genes B RCA I and B RCA2. The
two B RCA genes serve as important regulators of cell-cycle "checkpoint control"
mechanisms, leading to cell-cycle arrest and apoptosis, or to DNA repair. Germline
mutations of B RCA 1 and B RCA2 genes account for only 1 5 -20% of breast cancer
that clusters in families and less than 5% of breast cancer overall.
Sporadic brea t cancers are characterize by abnormalities that have been
identified in several genes including p53 and overexpression of several genes'
products including H ER-2 and estrogen.

7.1.

Hormones

and

tyrosine

kinase

receptors

(estrogen

and

H E R-2

receptors)

It has long been recognized that estrogen is involved in the pathogenesis of
breast cancer that expresses its receptor. In fact, at diagnosis, about 75% of breast
cancer patients are positive for estrogen receptor (ER) expression, and the
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re maining 25% of breas t cancer patient are ER negative [46] . Distinct gene
located on

eparate chromo orne

(6 and 1 4 respecti e ly) can produce two

differe nt ER: ERa and ERp. The two receptor
de elopment. The e receptor
some modificatIOn

have different roles in breast

are activated with estrogen binding and undergo

like dimerization and phosphorylation [47] . Increased

ERaJERP r atio in bre a t cancer a compare d with be nign tumors and normal tissues
uggest that ERa is mainly associated with bre as t cancer pathoge nes is , while ERP
can protect again t the mitogenic activ ity of estroge ns in pre -malignant les ions
[48] . Eve n though es trogen receptors are con idered as we ak prognostic factors ,
they are cons idered a s trong predictive factors for ide ntifying patients benefiting
from e ndocrine/targe ted therapy [49] .
Epidermal

growth

f actor

receptors

(EGFRs)

are

tyros ine

kinase

transme mbrane receptor . EGFR f amily cons is ts of four members : EGFR 1
(ErbB I IH E R 1 ), EGFR2 (ErbB2IHER2), EGFR3 (ErbB3IHER3), and EGFR4
(ErbB4IHER4).

These receptors share s imilar s tructures

cons isting of

an

extr ace llular ligand-binding domain, a short hydrophobic trans membr ane region,
and an intra-cytoplasmic tyros ine kinase domain. HER-2

eu oncoge ne is the mos t

frequently amplified oncoge ne in breast cancer [ 50] . Furthermore , an aggressive
phe notype of breas t cancer with poor prognosis were ass ociated with HER-2 over
e xpress ion in about 25 to 30% of bre as t tumors [5 1 ] .

7.2.

Non-hormonal factors (p53)

The tumor suppressor ge ne p53 was first identified in 1 979 and located on
chromosome 1 7 [52] . The p53 prote in acts as a checkpoint for several s timuli that
cause D A damage and apoptosis such as heat shock, hypoxia, r adiation and
16

chemIcal drug . Once activated, it accumulate

in the nucleus to lllcrea e the

expression of mdm2 and p2 1 WAF IICIP I , leadlllg to inhibition of cell proliferation
through G IIG2 cell-cycle arrest [53-57] . Thl
repair of D

check point control, leads to the

damage, or to apopto is if the damage cannot be repaired [58]. The

vast majority of mutation

seen in p53 are mis ense mutations rather than

truncations or deletions. While 10 s of the tumor-suppressive functions of this gene
are well recognized, e pres ion of mutant p53 is often seen at a high Ie el in cancer
and mutant p53 forms appear to be more stable than the wild-type tumor
suppres or.
Mutations of p53 are seen in more than 50% of all cancers. One of the best
known syndrome i Li-Fraumeni, in which mutation of p53 predisposes to a broad
range of cancer , including breast cancer, early in life [59] . The p53 mutations
occur in 30% of non-f amilial breast cancer patients [60] . It is considered the most
frequently mutated gene in human breast cancer [6 1 ] .

8 . Diagnosis

Large scale mammography screenings beside women's awareness of the
state of their breasts by palpation are the most important f actors regarding the early
detection of breast carcinoma and can result in decrease in mortality [62]. The
American cancer society recommends an annual screening mammography for
women who are more than 40 years old and at 25 years of age- with high risk of
breast cancer, especially those with B RCA I or BRCA2 mutations [62] . In the cases
of family history of breast cancer, manunography should be perfonned at a younger
age in order to ensure the detection of the onset of the carcinoma. Not only does the
diagnosis need to be rapid, but also it is important that the correct subtype of the
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breas t cancer be defined. Thi is crucial for the treatment of choice and depends on
the molecular profi le of the cancer. Other s i gnificant factors conce rning the
treatment are the lymph node s tatus and the tumor size [63].
After the initial

u picion of cancer based on mammography and/or

palpation ( uch a de nse mass in the radiograph, or a palpable lump), biopsy is
often extracted from the ite of the fmding. Micro copic e xamination of the biopsy
is the only

\

ay to confirm breast cancer. If cancer ce lls are prese nt in the biopsy,

further me as ures need to be undertaken, such as pe rsonal and family medical
his tories a we ll a ge ne ral signs of health.

9.

C u rrent therapeutic approache

Once a patient is diagnose d with breas t cancer and the s tage is dete rmine d
the mos t appropriate therapy should be de termined. Breast cancer the rapy consists
of s urgery to remove cancerous tissue , cytotoxic-chemotherapy, hormonal the rapy,
targeted therapy and radiotherapy.

9 .1.

Chemotherapy

Che motherapy can be referre d to as cytotoxic drugs use d to kill cancer ce lls .
If the bre ast tumor is large , the lymph nodes are concerned or the tumor is found
close to the ches t wall muscles and also in the case of inflammatory bre as t cancer
chemotherapy might be re commended bef ore surgery and sometimes even after the
surgery.
Chemotherapy drugs can be class ified into many groups according to how they
work, the ir chemical structure, and their re lationship to drugs .
Adjuvant chemotherapy

is used to kill those hidde n cancer ce l ls after surge ry.
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eOadjlH all1 chemotherapy:

GIving chemotherapy firs t to s hr ink a lar ge cancerou

tumor making it eas ier to be removed with surgery.
Several cytotoxic drugs are u ed in combinations to tre at breas t cancer .
These include combinations of cyclophosphamide, 5-flurour acil, me thotrexate ,
doxorubicin docetaxe l and paclitaxe l . Examples of combinations include : CMF,
which con

1

t of cyclopho phamide, methotrexate , and 5-flurouracil; FAC which

cons i t of 5 -flurouracil, doxorubicin, and cyclophosphamide .
Chemotherapeutic drugs are class ified into several groups and named
depending on their cytotoxic mechanism of action, phys iological be haviour, and
source of the drug. Class ifications include alkylating agents , anti-me tabolites ,
anthracyclines, and microtubule s tabilizers .
9. 1 .2. Alkylating agents.

They pre vent the cancer ce lls from proliferation by directly damaging the
DNA. These agent can work in all phases of the ce ll cycle . Alkylating agents are
used as therapy in many different cancers including le ukemia as we ll as lung,
ovar ian, and breas t cancer . Because these drugs damage the DNA, the y can cause
long-term damage to the bone marrow, and this can le ad to acute leuke mia, that is
dose -dependent.
Cyclophospham ide: IS a potent immunosuppress ant agent. This prodrug

should be oxidized to obtain the active me tabolite "phosphor amide mustard"
which e xert its cytotoxic effect via transfer of the alkyl groups to the DNA leading
to ce ll death [64].
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9. 1 .3.

Antim tabolite :

They inhibit pur ine and pyrimidine ba e productions leading to abnormal
D

and R
5-Fluorouracil: after it uptake by the cell, 5 -FU is converted into different

active metabolite ,
pecle .

\:

hich i incorporated into RN

a pyr imidine analogue,

into D A indu ing inhibition of DN

it

and produce aberrant mRNA
also

incorporated

ynthe ize and leading to cell cycle arres t

and apopto i [65,66].
9. 1 .4.

A n thracycline

Anthracycline are anti-tumor antibiotics that were introduced in the 1 960s .
They exert their cytotoxic action through four major mechanis ms including
inhibition of topoi omera e I I , blockage of DNA and RNA synthes is and DNA
trand s c i s ion, binding to cellular membranes leading to the alter ation of fluidity
and ion transport and fi nally gener ation of free r adicals through an enzyme
mediated r eductiv e process [67] .
Doxorubicin : FDA appro ed in 1 989. It can be used as adjuvant or neoadj uv ant

chemotherapy to treat ear ly s tage of br eas t cancer as well as HER2+ breast cancer
and metas tatic breast cancer patients [68] . Doxorubicin can be us ed in several
combinations such as with 5 -flurouracil or cyclophosphamide.

20

9. 1 .5.

M ic rotubule tabilizing ag nt . Include paclita el and docetaxel.

PacLitaxel (Taxol) : i

bre if olia) f ound in
re ult, interfere
di i ion.

orth

of a plant ongm from Pacific Yew tree (Tax us

merica [69] . Paclita el tabilize microtubule and a a

" ith the normal breakdown of microtubules during cell

hromosome

are

thu

unable

to

achiev e

a

metaphase spindle

configuration. Thi bl ck progre s ion of mito i , and prolonged activ ation of the
mitotic checkpoint trigger apopto i or rev er ion to the G-phase of the cell cycle
without cell di i ion [70] . It i recommended in adv anced breast cancer.

9.2.

H o r m o n a l/ E ndocrine Therapy

For more than a century, endocrine therapies for breast cancer patients have
been u ed. For brea t cancer treatment mo t endocrine therapies act as anti
proliferative of e tradiol on oestrogen receptor ( ER)-pos itive tumor in three ways ;
either e tradiol i i nh ibited f rom binding to E R by anti-es trogens or reduction of
e tradiol concentrations by ovarian ablation in premenopausal women or by
inhibition of aromatas e in pos tmenopausal women to block es trogen production.
The fir t targeted breas t cancer therapy wa

the anti-es trogen receptor

Tamoxifen and because three quarters of breast cancer patients express estrogen
and/or progesterone receptors Tamoxifen is us ed as a firs t line therapy f or the
treatment of breas t cancer. Even though it was found to be useful in treating
es trogen pos itive breas t cancer in both early and adv anced cases, due to its partial
es trogen agonist effect it had many s ide eff ects s uch as the risk of endometrial
cancer [ 7 1 72] .
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Aromatase inhibitors are a class of endocrinelhonnonal therapy. The y act by
inhibiting the

cytochrome

P-450 depende nt e nzyme

aromatase ,

which is

res pons ible for converting adrenal androge n subs trates to estroge n . It is cons idere d
the only ource of endoge nous estrogen in pos tme nopausal women [ 7 3 ] . Aromatase
inhibitors are di ided into two groups : reve rs ible and irre vers ible inhibitors .
Reve rsible inhibitors s uch a Arimide x will block the e nz yme f o r a limited time .
The second-line therapy af te r f ailure of Tamoxifen is Fulvestrant (se lective
oes trogen receptor down-re gulator) and also a compe titor with es troge n for binding
to the estrogen receptors [74]. It is also used for the third-line the rapy after f ailure
of tamoxifen and aromatase [75].

9.3.

H E R-2 Recepto r Ta rgeted Therapy

A lmost 3 0% of breast cancer patients are presented with Her-2 prote in over
e xpress ion due to the ampl ification of Her-2 ge ne [76] . Her-2 overe xpress ing breas t
cancer i s known f or its aggress ive nature and short disease -f ree periods [50,77,78] .
Tras tuzumab, a recombinant humanized monoclonal antibody targeting Her-2
receptor, proved its efficacy in the treatment of bre ast cancer. Tras tuzumab targe ts
the e xtrace llular domain of H E R-2 receptor le ading to blockade of several s ignaling
pathway s uch as phosphatidylinos itol 3 -kinase and mitogen-activated prote in
kinase and conseque ntly to ce l l cycle arres t and apoptos is [79] . Due to its severe
cardiotoxicity, the use of tras tuzumab draws a big question towards its safe ty for
patients .
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1 0.

Aims of the Re ea rch
Bre as t cancer is one of the mos t common malignancies among women.

Genomic studie ha e increased our understanding of the bre as t cancer disease , and
in combination with scree ning programs , it has improved survival outcomes of
bre ast cancer patie nts . Re markable progress has bee n made in the treatment of
brea t cance r

0

er the ye ars , such as hormonal therapy, which depe nds on tumor

sens itivity to endocrine manipulation, as we ll as some targe ted the rapies that can be
use d e lective ly in tho e patients most likely to be nefi t. However, despite these
advances , controvers ies re main, patie nts die , and a cure re mains elus ive .
The SMARCAD 1 (SWIISNF-related, Matrix-ass ociated, Actin-depe nde nt
Regulator of Chr omatin, containing DEADIH box 1 ) prote in is the human ortholog
of yea t

Saccharoln) ce cerevisiae

Fun30 (Function Unknown Now 30) prote in

[80,8 1 ] . The Fun30 prote in is a me mber of the Snf2 he licase motif -containing
prote in families , which are known to act as ATP-depende nt DNA transclocators
[82,83]. Previous studies have s hown that yeast Fun30 de le tions are res is tant to
ultraviole t (UV) radiation [ 84, 8 5 ] . The ove r-express ion of Fun30 has bee n shown
to affect chromosome s tability, integrity, and segre gation [85J. Similarly, Fft2, the
Saccharomyces pombe

homologue of Fun30, was f ound to play a role in

maintaining chromosomal s tability and for the mainte nance of the chromatin
str ucture required f or kine tochore assembly [86] . In addition, Fun30 was shown to
interact genetically w ith Cse4 (the histone variant at ce ntrome res ) and ChIP-se q
data confmned Fun30 binding to ce ntromeres [ 8 7 ] .
Fun30 has also bee n found to play a role in the promotion of the ce ll cycle
along with origin recognition s ubunit ORC 5 . Double mutants of both Fun30 and
OCR5 were f ound to accumulate in the G l and early S phase us ing F ACS analysis
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[88) . ChIP-seq data shows that Fun30 is also located at Autonomously Repl icating
equences (ARS) sugge ting a role of Fun30 in repl ication [87) . Fun30 has also
been shown to be a potential cyelin-dependent kinase (Cdk l )/Cdc28 substrate [89] .
As for its biological activity it has recently been shown that purified Fun30
forms a homodimer of around 250 kDa and is able to hydrolyze ATP, bind to DNA,
mononueleosomes and nueleosomal arrays. Fun30 was also shown to have a
remodeling acti ity using restriction enzymes accessibility assay. In addition,
Fun30 was found to be more efficient in exchanging histones dirners than in
repositioning nucleosomes. These biochemical assays provided the first evidence
that Fun30 is an ATP-dependent chromatin remodeler [ 8 1 ] .
Other studies have also implicated Fun30 in heterochromatin regulation
[88]; [86] and in DNA double strand break ( DSB) repair by homologous
recombination [90 9 1 ] . Fun30 was found to facilitate long-range DNA end
resection in yeast cells and this required the ATPase activity of Fun30 and other
resection proteins such as Sgs l and Exo l . The authors suggested that the activity of
Fun30 made the DNA more accessible to DNA repair machinery.
SMARCAD 1 , the human ortholog of Fun30, is a DEADIH box-containing
helicase, which includes proteins essential for replication, repair, and transcription.
In addition to two DEADIH box and an ATP-binding motifs within SMARCAD l ,

it has a putative nuelear localization signal and several regions that may mediate
protein-protein interactions. Expression analysis indicates that SMARCAD 1
transcripts are ubiquitous, with particularly high levels in endocrine tissue [92 ] . The
gene for S MA RCAD I has been mapped to the chromosome 4q22-q23m, a region
rich in break points and deletion mutants of genes involved in several human
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tissue leiomyosarcoma, hepatocellular carcinoma, and
hematologic mal ignancies [80,92]. It has been recently reported that the binding
sites of endogenous

MAR AD l lKIAA 1 l 22 are frequently found in the vicinity

of transcriptional start ite [93J . Moreover, human SMARCAD 1 overexpression
was observed in E IA-e pressing cell line with increased capacity for gene
reactivation

event

by

genolllic

rearrangements

suggesting

that

human

SMARCAD 1 may play a role in genetic instability development [92 ] . S MARCAD 1
has also been

hown to work at replication origin sites in order to facilitate

deacetylation of newly assembled histones [94] . Interestingly, a recent paper
suggested that S MARCAD 1 ju t like Fun30, is involved in DNA end resection and
was recruited to DNA damaged sites were IDA.X is phosphorylated. Silencing the
SMARCAD 1 gene affected the recruitment of Replication Protein A (RP A)
indicating reduced formation of single-stranded DNA as in yeast cells [90] . These
data together suggest an evolutionarily conserved role for the Fun30 and
SMARCAD 1 chromatin remodelers.
Dr. Attoub Laboratory have previously shown that the breast cancer cells
estrogen receptors ( E R)-negative MDA-MB-23 1 and MDA-MB-23 1 - 1 833 as well
as estrogen receptors (ER)-positive cells MCF-7 and T47D expressed a high level
of SMARCAD I protein in comparison with the human breast epithelial cells
NHME.
My master's p roj ect aims to i nvestigate the i m pact of specific silencing
of S MA RC A D I on human b reast c a ncer cell proliferation, colony growth in
soft agar, m orphology, migration and invasion using human b reast cance r
cells estrogen receptors (E R)-negative MDA-M B-23 1 .
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Chapter 2
Materials &
Methods
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2 . 1 Cell c u l t u re a n d reagent

Human brea t cancer cells M DA-MB-23 1 , MDA-MB-23 1 - 1 83 3 , MCF-7
and T47 D were maintained in DMEM medium supplemented with antibiotics
(penicillin 50U/ml; streptomycin 50�glml) ( Invitrogen, Cergy Pontoise, France)
and 1 0% fetal bovine serum (FBS, Biowest, Nouaille, France) at 37°C. The culture
medium wa changed every three days and cells were passed once a week when the
culture reaches 95% confluence. The human breast epithelial cells NHME were
maintained in MEBMT

1

plus SingleQuots™ of Growth Supplements ( Lonza,

Walkerville M D, USA). In all experiments, cell viability was higher than 99%
using trypan blue dye exclusion. Paclitaxel was purchased from Sigma-Aldrich
( S igma-Aldrich, Saint-Quentin Fallavier, France). Frondoside A of 99.9% purity
was purified from Cucumaria frondosa, harvested near Stonington, Maine and
checked by NMR as previously described [95,96] . SMARTvector 2.0 Lentiviral
shRNA particles (Dharmacon Thermo Scientific, US) can directly bind to cells and
deliver their genetically engineered RNA genome to the cytoplasm. The
SMARTvector 2.0 includes a turboGFP reporter gene to faci litate assessment and
optimization of transduction efficiencies. The SMARTvector 2 . 0 also contained a
puromycin resistance gene for selection and isolation of c lonal populations when
generating stable cell l ines.

2.2 Establishment of Stable SMARCAD I silencing in b reast c a n ce r cells

MDA-MB-23 1 cells were seeded at a density of 20,000 cells / well into 96well plates, i n the presence of the serum and allowed to attach for 24h. Cells were
transfected

w ith

SMARTvector

2.0

Lentiviral

shRNA

particles

targeting

SMARCA D I or SMARTvector 2 .0 Non-Targeting control part ic les (Dharmacon
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Thermo Scientific, US). Selection of cells stably expressing SMARCAD l -shRNA
and the Control-shRNA started 72 h post-transfection following the manufacturer's
in truction

( Dharmacon Thermo

cientific, US). Briefly, growth medium was

a pirated from the cells and replaced with fresh selection medium containing 1 0
)lg/mL o f puromycin. Puromycin-containing medium was replaced every 2-3days
with fre hly prepared selection medium, and selection of stable cells expressing
SMARCAD l -shRNA or Control-shRNA was completed in approximately 4 weeks
from the beginning of selection. Multiple clones and pools of clones were
expanded harve ted, and prepared for western blot analyses of SMARCAD 1
e pression.

2.3 Western blot a n a lysis of SMARC A D I p rote i n e x p ression

Total cellular proteins from stably trans fee ted cells with SMARCAD 1 shRNAs and control-shRNA were isolated using RlPA buffer (25Mm Tris.HCI pH
7.6

1 % nonidet PAO, 1 % sodium deoxycholate, 0. 1 % SDS, 0.5% protease

i nhibitors cocktail ( S igma, Steinheim, Germany),

1 % phenylmethylsulfonyl

fluoride, and 1 % phosphatase inhibitors cocktail (Themlo Scientific, Rockford,
USA). The whole cell lysate was recovered by centrifugation at 1 4 ,000 rpm for 20
minutes at 4°C to remove insoluble material and 30-50 )lg of proteins were
separated by sodium dodecyl sulfate (SDS) polyacrylamide gel for SMARCAD 1
expression. A fter electrophoresis, proteins were transferred on a nitro-cellulose
membrane, blocked with 5% non-fat milk and probed with S MARCAD I (Abeam,
Bristol, UK, 1 : 5 00) and p-actin (Santa Cruz, Cali fornia, USA, 1 : 1 000) antibodies
overnight at 4°C. The blot was washed, exposed to secondary antibodies and
visualized using the ECL system ( Perkin, Waltham, MA, US).
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2.4 Cell proliferation a ay
Stable

MDA-M B-23 1

cells

transfected

with

SMARCAD l -shRNAs

(SMARC D l - hR A l & S MARCAD l -shRNA3) or control sequences (Control
shRNA) were plated at the density of 50,000 cells into six-well tissue culture
dishes supplemented with 1 0% FBS. Cancer cells were trypsinized, collected in 1
ml o f medium and counted at an appropriate dilution every day for five
consecuti e days.

2.5 Soft-agar colony formation assay
A layer of agar containing I ml of 2.4% low melting temperature agar (Bio
Rad) di solved in distilled water was poured into wells of a 6-well cell culture dish
and allowed to set at 4°C for 5 minutes then incubated at 37°C for 30 min. A
second layer (2.9 ml) containing 0.3% of low melting agar dissolved i n growth
media containing stably transfected cells with S MARCAD I -shRNAs or with
control-shRNA (2 0 x 1 03 cells / ml) was placed on top of the [lrst layer and allowed
to set at 4°C for 5 minutes. After 30 minutes to I -hour incubation in the humidified
incubator at 3 7°C, growth medium (2 ml) was added on top of the second layer
and the cells were incubated in a humidified incubator at 37°C for 3 weeks.
Medium was changed twice a week. At the end of the experiment, colonies were
stained for 1 hour with 2% Giemsa stain, and incubated with PBS overnight to
remove excess stain. The colonies were photographed and scored.
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2.6 Cel l u l a r Morpholog

Cells were seeded on four-chamber culture slides at a density of 25 000
cells/chamber. After 48 h, chambers were removed· cells were washed with PBS,
fixed in 4% paraformaldehyde for ten minutes at room temperature, washed with
PBS and perrneabilised with 0. 1 % Triton X- I OO in PBS for 1 0 min. Then, the actin
cyto keleton was tained with rhodamine phalloidin ( Invitrogen Molecular Probes,
Oregon, US) and the nuclei were stained with 4 ' , 6-diamine-2-phenylindole
dihydrochloride (DAPI) ( Invitrogen Molecular Probes, Oregon, USA). The cells
were then photographed using an Olympus fluorescence microscope (Olympus
IX7 1 , Japan) for the analysis of theirs morphology.

2.7 Wou n d healing m otility assay

MDA-MB-23 1 cells stably transfected with S MARCAD I -shRNAs or
control-shRNA were grown i n six-well tissue culture dishes until confluence.
Cultures were incubated for 1 0 min with Moscona buffer. A scrape was made
through the confluent monolayer with a plastic pipette tip of l rum diameter.
Afterwards, the dishes were washed twice and incubated at 3 7°C in fresh DMEM
containing 1 0% fetal bovine. At the bottom side of each dish, two arbitrary places
were marked where the w idth of the wound was measured with the inverted
microscope (obj ective x4). Motility was expressed as the mean

±

SEM of the

difference between the measurements at time zero and the 6 and 24h time period.
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2.8 M atrigel i n v a ion a

a

The invasiveness of the breast cancer cells MDA-MB-23 1 stably transfected
with S MARCAD l -shRNAs or control- hRNA was tested using BD Matrigel
lnva ion Chamber (8-).lm pore size; BD Biosciences Le Pont de Claix, France)
5
according to manufacturer's protocol. Briefly, Cells ( 1 x 1 0 cells in 0.5 mL of
media) were seeded into the upper chambers of the system, the bottom wells in the
system were filled with DMEM supplemented with 1 0% fetal bovine serum as a
cherno-attractant and then incubated at 3 7°C for 24h. Non-penetrating cells were
remo ed from the upper surface of the filter with a cotton swab. Cells that have
migrated through the Matrigel were fixed with 4% formaldehyde, stained with
DAPI and counted in 25 random fields under a microscope. The assay was carried
out in duplicate and repeated three times for quantitative analysis.

2.9 The O ris™ Collagen I Cell I nvasion Assay

This experiment was used to investigate the impact of S MARCAD 1
silencing on MDA-MB-23 1
extracellular matrix

cell invasion

in

comprised of collagen

within a 3 -dimensional

vitro

type

I

from

rat

tail

CAMS

Biotechnology, Abingdon, UK). Cells were seeded at 1 00,000 cells / well and
allowed to attach overnight onto coated plates. Once the cells formed a confluent
monolayer, the silicone stoppers were removed and the cells were incubated for 48
h invasion. Cells were then labeled with Calcein AM ( Invitrogen) and images were
acquired, in the absence of the mask, by use of Olympus fluorescence microscope.
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2. 1 0 Cel l u l a r viability

MDA-MB-23 1 -Control-shRNA,

MDA-MB-2 3 1 -Smarcad l -shRNA l

and

MDA-M B-23 1 -Smarcad I -shRNA3 cells were seeded in 96-well plates at a density
of 5 ,000 cells / well. After 24h, cells were treated for 24h with increasing
concentration of frondoside A (0.0 1 -5 � M ) or pac1itaxel ( l -64nM) in triplicate.
Control cultures were treated with 0. 1 % DMSO. The effect of the drugs on cell
viability was detennined using a CellTiter-Glo luminescent cell viability assay
(promega Corporation Madison, USA), based on quantification of A TP, which
signals the presence of metabolically active cells. Luminescent signal was
measured using GLOMAX Luminometer system. Data were presented as
proportional viability (%) by comparing the treated group with the untreated cells,
the viability of which was assumed to be 1 00%.

2. 1 1 Statistical A n alysis: In the above experiments, results were expressed as

mean

±

S.E.M. The difference between experimental and control values were

assessed by ANOVA followed by Dunnett' s post-hoc multiple comparison test.
P<0.05 was taken to indicate a sign ificant difference.
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C h apter 3
Results

33

3. 1

H u ma n

Breast Cancer Cell

Line

0 e r-exp ress

S M A RC A D l :

The

expression of the SMARCAD 1 was initially investigated in the human breast
epithelial cells NHME in comparison with several human breast cancer cell lines
including ER-negative MDA-MB-23 1 and MDA-MB-23 1 - 1 83 3 and ER-positive
MCF-7 and T470. Western blot analysis of crude protein Iysates ( 1 00 )lg) prepared
from these cell

was performed, using the mouse polyclonal antibody directed

against SMARCAO l . We observe in Fig. 1 that all the cells exhibit mainly an
immunoreactive band with a molecular weight of 1 1 7 KD, corresponding to the
e pected size of SMARCAD l . Together with this band, an additional minor band
of 90KD was also detected in lysates from all the cells (Fig 1 ).

3.2 S M A RC A D I silencing i n b reast cancer cells M D A- MB-23 1 : Cells were

stably transfected with two different designs of SMARTvector 2 .0 Lentiviral
shRNA particles targeting SMARCAD 1 . Control cells were transfected with
SMARTvector 2 .0 Non-Targeting control particles. The positive clones ( 1 0 to 1 2
from each design) were selected under puromycin (Fig 2 A) and analyzed using
western blot to confll1n specific SMARCAD 1 silencing. The two different design
of shRNA targeting S M ARCAD 1 induced 99% decreased i n the SMARCAD I
protein level ( S MARCAD l -shRNA l , and S MARCAD 1 -shRNA3). The selectivity
of this silencing was confirmed by the fact that no impact on SMARCAD 1 protein
was observed in the cells transfected with shRNA control particles (control
shRNA) (Fig 2B). The selected c lones were GFP positive (Fig 3).

34

M ol . w t ( k O a )

Smarcad1
J3-A ctin

� 117
� 90

J'liiiiiiliiiriiil.ii;l � 4 5
T"
w
C""l
N

en

:E
<{
•

C

:E

C""l
C""l
co
..,..

..,..
C""l
N
•

"-

u..
•

U

:E

:E

::I:
Z

en

:E
<{
c
:E
•

Figu re 1 : Western blots a nalysis of S MA RC A D I protei n expression III
human breast cancer cell lines M DA-M B-23 1 M DA-MB-23 1 - 1 83 3 MCF-7 and
T47 D and in the normal human breast epithelial cells NHME.

35

A)

C l o n e s tra n sfected w i t h C o n t r o l - s h R N A

Sm arcad 1
l3 -Actin

C l ones tra n sfected w it h Sma rcad 1 -s h RN A 1
. .
_
_
.:...�
...,
....
_
.
rool wt [1<04)
...,....
_
_
_
_
= 1 17
= 9 11

Smarcad1
l3 -Acti n
M
"
m
�

.,
c:
0

:<
ci:
:<

C3

'"
.,
c:
0

u

M
m
c:
0

...
m
c:
0

C3

C3

...,
.,
c:
0

C3

a

C l o n e s t r a n sfected w i t h S m a r ca d 1 - s h R NA3

Sma rcad 1

,

i _------�------�
,..iiii_
__
_
_
_
_
_
_
_
_
_
_
_
�____

FdoLwt

{k Oa)

= 1 17
<=== 9 0

I3-Acti n

B)

M DA-M B 2 3 1 tran sfected clones:

S m a rc a d 1
I3-Actin

45

<{
z
a:
.c
<II

..-

"0
..

.."0
('CI
(.)
...
('CI

,

E

0
u

<{
z
a:
.c

'(l

E

CJ)

....,

<{
z
a:
.c
'(l

.."0
('CI
(.)
..
('CI

E

CJ)

Figure 2 : Western blots a n a lysis of S MA RC A D I p rotei n expression in: A &
B) stably transfected M DA-MB-2 3 1 -Control-shRNA (Clone 4), M DA-MB-23 1 SMARCA D l -shRNA l (Clone 3 ), and M DA-MB-23 1 -SMARCAD l -shRNA3
(Cl one 3) cel l s .
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M DA-M B 231

tran sfected clones:

Cont rol-sh RNA

S m a rcad1 -sh RNA 1

Sma rcad 1 -s h R N A 3

Figu re 3 : I m m u n o fl uorescence a n alysis of green fluorescence protei n
expression : the three selected clones from the control and the SMARCAD I
si lenced cel ls were photographed for their G F P expression.

3.3 S MAR C A D I silenci n g decreased M DA-MB-23 1 cell proliferation and
colonies growth i n soft agar: To test the ability of SMARCAD 1 to interfere with
cancer cell proliferation, Control-shRNA cel l s and their SMARCAD I silenced
counterparts

S MARCAD l -shRNA l

and

SMARCAD l -shRNA3

cells

were

compared for their growth rates. As shown in Fig. 4 A, SMARCAD 1 silenced cells
exhibit slower proliferation rates, as shown at days 3 to 5 in culture. At day 5 , the
inhibition

was

55

and

35%

respectively

for

S M A RCAD I -shRNA 1

and

SMARCAD l -shRNA3 cell s. Similarly, SMARCA D I silencing strongly inhibited
the ability of M DA-MB-23 1 cell s to form colonies in soft-agar ( Figure 4B & C).
This interesting data prompted us to investigate the impact of SMARCAD 1
silencing on the migration and invasion of M DA-M B-23 1 human breast cancer
cells.
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Figu re 4 : I mpact of S M A RC A D l silencing o n the proliferation and colon ies
growth of M DA-MB-23 1 b reast cancer cells. A) Control and SMARCA D I
silenced cells were seeded into six-well tissue culture dishes (50,000 cells /dish)
and counted daily for 5 days. Data are means ± SEM of 3 independent
experiments. B) Inhibition of anchorage-independent colonies growth by stable
3
silencing of SMARCAD I in M DA-MB-23 1 cells. 20x I 0 of M DA-M B-23 1 Control-shRNA, M DA-M B-23 l -S MARCA D l -shRNA l , and M DA-MB-23 1 SMARCA D l -shRNA3 cells were plated in 0.3% soft agar. Three weeks later,
colonies were stained with Giemsa and scored. Statistical differences obtained at
* P<0.05, * * P < 0.0 1 , and * * * p < 0.00 1 . C) Pictures of the colonies formed in
soft agar were photographed (top panel), and representative single colonies were
enlarged 40 times (bottom panel).
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3.4

ReA D !

M

ilencing impairs b reast cancer ceU migration and i n vasio n :

Breast cancer patients are a t high risk o f recurrence i n the form of metastatic
disease. Meta tasis starts with the acquisition of a scattered phenotype and cell
migration in the primary tumor, leading to local tissue invasion and entry into
lymph or blood

e sel . First, the actin cyto keleton of these cancer cells was

stained with rhodamine phalloidin and theirs nucleus was stained with DAPI for the
analysis of their morphology. Contrast and fluorescent microscope analysis shows
that SMARCAD l -shRNA l and SMARCAD 1 -shRNA3 cells have stronger cell-cell
adhesion in comparison with Control-shRNA cells (Fig. SA & B). Secondly, we
examined the effect of S MARCAD I silencing on cellular migration of MDA-MB23 1 cells. Using wound-healing experiments perfom1ed on sub-confluent cell
cultures, we show that SMARCAD I silencing inhibited by 67.7 and 50.8% the
migration

of

the

SMARCAD l -shRNA l

and

SMARCAD l -shRNA3

cells

respectively at the 6h short incubation time considered ( Fig. 6A & B) indicating
that the inhib ition of cellular migration is not due to the inhibition of cell
proliferation. Control-shRNA cells were able to achieve a complete wound healing
within 24h, while S MARCAD I -shRNA 1 and S MARCAD I -shRNA3 cells were
unable to fully colonize the wounds at this time period ( Fig. 6A & B).
F inally, we examined the impact of S MARCAD 1

silencing on the

spontaneously invasive MDA-MB-23 1 cells. As shown in Figure 7A & B,
selective

and

stable s i lencing of S MARCAD 1

strongly reversed

cellular

invasiveness of M DA-MB-2 3 1 cells in matrigel matrix as well as in Oris invasion
assay (Figure 7 A & B). All together, these results strongly suggest that
S MARCAD 1 may play an important role in breast cancer cell migration, invasion
and metastasis.
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A)
M orphology:

Control-shRNA
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B)

M DA-M B 2 3 1 transfected clones:
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Control-sh RNA
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Figure 5: S MAR CA D I silencing impai rs M DA-M B-23 1 breast cancer cell
migration and invasion : Morphological changes observed in the S MARCAD 1
silenced M DA-MB-23 1 cells were photographed using an inverted microscope
(A). The actin cytoskeleton was then analyzed wlder a fluorescence microscope
at three different magn i fications after staining with the rhodamine phal loidin
solution ( B).
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Figure 6 : S MARCAD I silencing i m p a i rs MDA-M B-23 1 b reast cancer cell
migration and invasio n : Wounds were introduced in control and SMARCAD I
silenced confluent mono-layers cultured in the presence of serum. The mean
distance that cells travel l ed from the edge of the scraped area for 6 and 24h at
3 7°C was measured in a blinded fashion, using an inverted microscope. Data are
means ± SEM of four independent experiments (A & B).
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Figure 7 : S MA RCA D I silencing i m p a i rs MDA-MB-23 1 b reast ca ncer cell
m i gration a n d i nvasio n : M DA-MB-2 3 1 -Control-shRNA, M DA-MB-23 1 SMARCAD I -sbRNA l , and M DA-MB-23 l -SMARCA D l -shRNA3 cel ls were
incubated for 24h in the presence of serum. Cells that invaded into Matrigel were
scored as described in Materials and Methods (A). Cells were incubated for 48h
onto an Oris collagen type I cell invasion assay plate. Cell invasion images were
acquired by fl uorescence microscope ( B). All experiments were repeated at least
three times. * Significantly different at P < 0.05, * * Significantly different at P <
0 .0 1 , * * * Significantly different at P < 0 . 00 1 .
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3.5 I m pact of

M A RC

Dl

ilencing o n the anti-ca ncer effect o f paclitaxel a n d

Fro n d o ide A i n vitro : The effect of paclitaxel ( I -64oM) on the viability of the

MARCAD I - hRNA I , and SMARCAD 1 -shRNA3 breast cancer

Control-shRNA,

cells was detennined after 48h incubation ( Fig. 8A). No significant enhancement of
iabi lity wa observed following treatment with paclitaxel in

the inhibition of cell
the SMARCAD I

ilenced cells (Fig. 8A). Interestingly, high concentrations of

Frondo ide A ( 2 . 5 - 5 �), enhances the i nhibition of cellular viability in the
S MARCAD l -shRNA l cells as shown in Fig. 8 B . This means that silencing of
SMARCAD 1 my increases the sensitivity of the breast cancer cells MDA-MB-23 1
to Frondoside A. However, the SMARCAD l -shRNA3 cells, does not enhance the
sensitivity of the cells to Frondoside A.
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Figure 8 : SMARCAD I silencing e n h ances t h e i n h ibition of cellular viability
i n duced b y Frondoside A b u t n o t by p ac litaxel. Control and SMARCAD 1

silenced M DA-MB-23 1 cells were treated with vehicle (0. 1 % DMSO) and the
indicated concentrations of pac1itaxel (A) or Frondoside A (B) for 48h. Viable
cells were assayed as described in Materials and Methods. All experiments were
repeated at least three times. * Significantly different at P < 0.05, * *Significantly
different at P < 0.0 1 , * * *Significantly different at P < 0.00 1
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Discus sion
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Breast cancer is the most corrunon cancer among woman, and it

1S

responsible for 1 .3 80.000 cases and 450.000 deaths each year worldwide [97] .
Invasion leading to metastasis represents the most devastating attribute of cancer.
Genes a sociated with in asion and metastatic virulence provides an aggressive
edge in survival and proliferation during colonization of the metastatic site. Breast
cancer patients are at high risk of recurrence in the fOlm of metastatic disease.
The SMARCAD I (SWIfSNF-related, Matrix-associated, Actin-dependent
Regulator of C hromatin, containing DEADIH box 1 ) protein is the human homolog
of yeast Fun30 (Function Unknown Now 30) proteins. These proteins are members
of the Snf2 helicase motif-containing protein families, and are known to act as
ATP-dependent DNA transelocators. Previous studies have shown that yeast Fun30
deletions are resistant to ultraviolet (UV) radiation. The over-expression of Fun30
has been shown to affect chromosome stability, integrity, and segregation. Fun30
has also been shown to be a potential cyelin-dependent kinase (Cdk l )/Cdc28
substrate. The S MA RCAD I is a DEAD/H box-containing helicase, which ineludes
proteins essential for replication, repair, and transcription. Expression analysis
indicates that SMARCAD I transcripts are ubiquitous, with particularly high levels
in endocrine t issue. The gene for SMARCAD 1 has been mapped to the
chromosome 4q22-q23m, a region rich in break points and deletion mutants of
genes involved in several human diseases, notably soft tissue leiomyosarcoma,
hepatocellular carcinoma, and hematologic malignancies. Our laboratory have
previously shown that the breast cancer cells ER-negative MDA-MB-23 1 and
MDA-MB-23 1 - 1 833 as well as ER-positive MCF-7 and T47 D expressed a h igh
level o f SMARCAD l in comparison with the normal breast epithelial cells NHME.
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In this master research project, we investigated the impact of specific
silencing o f SMARCAD 1 on human breast cancer cell proliferation growth on soft
agar, morphology migration and invasion using human breast cancer cells estrogen
receptors (ER)-negati e M DA-M B-23 I . In this respect, the M DA-MB-23 1 cells
were stably transfected with two different design of SMARTvector 2.0 Lentiviral
shRNA particles targeting SMARCAD 1 . Control cells were transfected with
SMARTvector 2.0

on-Targeting control palticles. The positive clones ( 1 0 to 1 2

from each design) were selected under puromycin and the GFP positive clones
were analyzed using western-blot to confirm specific SMARCAD I silencing. The
two different design of siRNA targeting SMARCAD I induced 99% decreased in
the

SMARCAD I

protein

level

( S MARCAD l -shRNA l

and

SMARCAD l 

shRNA3). The selectivity of this silencing was confmned by the fact that no impact
on SMARCAD 1 protein was observed in the cells transfected with shRNA control
particles (control-shRNA). We demonstrated for the first time that silencing of
S MARCAD 1 resulted in a significant inhibition of cellular proliferation and
colonie

formation in soft agar as wel1 as cellular migration and invasion. All

together, these results strongly suggest that S MARCAD I may play an important
role in breast cancer growth and metastasis.
It has been previously reported that deletion of Fun30, was associated with a
delay i n the cell cycle leading to an inhibition in the proliferation (AI Marzouqi et
ai, unpublished data). Similarly, we report in this study that silencing of
SMARCAD 1 , the mammalian homologue of Fun30, is also associated with an
inhibition of cell proliferation leading to a decrease in the colony growth.
Metastasis is the maj or cause of morbidity and mortal ity in breast cancer
patients that causes nearly half a million deaths each year worldwide [98] . This
46

multi-step process in olves increased motility of the tumor cells, invasion of nearby
tissue

and intravasation into blood and lymphatic circulation. Finally breast

carcinomas colonize distant organs, mainly the brain liver, bone and lungs. Patients
with metastatic cancer have a low chance of achieving long-term survival after
chemotherapy [99) . Metastasis can occur at later stages during therapy or several
years following treatment.
Therefore, to wlderstand the molecular mechanisms of cancer metastasis, it
IS

necessary to identify the genes whose alterations accumulate during cancer

progre ion as well as the genes whose expression is responsible for the acquisition
of metastatic potential in cancer cells which can be classified into three groups:
metastasis initiation, metastasis progression and metastasis virulence genes [ 1 00).
Initiation of metastatic genes involves promoting cell motility, invasion, epithelial
mesenchymal transition (EMT) , extracellular matrix degradation, bone marrow
progenitor mobilization and angiogenesis [ 1 0 1 ) . In this study, we observed from the
morphology of S MARCAD I
SMARCAD I

silenced MDA-MB-23 1 , that the silencing of

is associated with stronger cell-cell adherence leading to the

inhibition of cellular migration and invasion.
These results are in total agreement with recent work demonstrating that the
silencing of BRG 1 , a core component of the SWI/SNF chromatin-remodeling
complex, l ike the silencing of S MARCAD 1 markedly inhibits breast cancer
cell proliferation and reduces M M P-2, thereby inhibiting the ability of cells to
migrate and to invade [ 1 02 ) . However, both studies are in contrast with previous
publications reporting that chromosomal instability is associated with higher
expression of genes implicated in Epithelial-Mesenchymal Transition, cancer
invasiveness, and metastasis and with lower expression of genes involved in cell
47

cycle checkpoints, D A repair, and chromatin maintenance [ 1 03] and that the
alterations in chromatin play an important role in breast cancer progression and
meta tasis [ 1 04] .
Frondoside A i
cucumber

a triterpenoid glyco ide isolated from the Atlantic

Cucumaria jrolldosa

[ 1 05 ] . Low concentrations of Frondoside A inhibit

the growth and induced apoptosis of human pancreatic, leukemia, lung and breast
cancer cells via ca pase activation [ 1 06- 1 09]. It has also been demonstrated that
Frondoside A has an anti-invasive and anti-metastatic effect on human breast and
lung cancer cells [ 1 08, 1 09] . Frondoside A enhances breast cancer cell death
induced by the chemotherapeutic agent Pac1itaxel [ 1 09]. Pac1itaxel has considerable
clinical acti ity against a variety of malignancies including breast cancer.
Paclitaxel, known to stabilize microtubules, inhibit cell division and induces death
of breast cancer cells [ 1 1 0] .
I n the current study, w e investigated the possible contribution of
SMARCAD I silencing to the anti-cancer effect of Paclitaxel and Frondoside A
vitro.

in

No additional inhibition of cell viability was observed after treatment with

Pac1itaxel in the silenced S MARCAD 1 cells in comparison with control-shRNA
cells. However, the inhibition of cellular viability with high concentrations of
Frondoside A was enhanced in the SMARCAD l -shRNA l cells. This may suggest
that we can increase the sensitivity of the breast cancer cell l ines to Frondoside A
by silencing S MA RCAD I . This result is consistent with previous study showing
that the loss of SMARCAD 1 impairs end resection and recombinational DNA
repair, and renders cells hypersensitive

to

DNA damage resulting from

camptothecin or poly(ADP-ribose) polymerase inhibitor treatments [90] .
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In conclusion, we have identified that specific silencing of SMARCAD 1
decrea e cel lular proli feration, colony growth, migration and invasion of the human
brea t cancer cells estrogen receptors (ER)-negative MDA-MB-23 1 . This study is
the first demon tration of the role of SMARCAD 1 in human breast cancer
progre sion. Increa ed SMARCAD 1 expression may facilitate tumor progression
by enhancing cell growth, migration and invasion. Our results imply that
SMAR AD 1 may serve as a prognostic marker as well as a potential therapeutic
target for breast cancer.

Persp ec tives of the p resent stu dy
1 . I m pact o f S MA R C A D silencing o n trans-e n d othelial migration of MDA
M B-23 1 ceUs t h rough H UV E C cells: Briefly, transwell filters will be coated with

collagen type I and allowed to dry for I hour. HUVECs 1 50,000/well will then be
seeded onto the rehydrated membrane and allowed to grow for 24 hours until a
s
confluent monolayer is fonned. Then, l x l O of the breast cancer cells MDA-MB23 1 stably tran fected with SMARCAD l -shRNAs or control-shRNA will then be
loaded on top and incubated overnight in 0. 1 % serum, the bottom wells in the
system will be fi l led with DMEM supplemented with 1 0% fetal bovine serum as a
cherno-attractant.

on-penetrating cells in the upper chamber will removed with a

cotton swab, whereas MDA-MB-23 1 in the bottom will be fixed with 4%
formaldehyde, stained with DAPI and quantified for GPF expression in 25 random
fields under a m icroscope [ 1 1 1 ] .
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2 . I m pact of S M A RC A D
u p p re

ilencing on the exp ression of the m etastatic

or gene E-cad heri n : It is well known that disruption of cell-cell adhesion

during cancer progression is the initial stage required for the acquisition of invasive
properties and characterized by a decreased expression of E-cadherin. E-cadherin, a
calcium-dependent, cell adhe ion molecule, is considered as a tumor suppressor in
breast cancer [ 1 1 2] . Decrease of E-cadherin expression is a critical and necessary
event required in the disruption of cell-cell adhesion and thus for the acquisition of
invasi e

phenotype

of vruious

tumors

including

breast

cancer.

In

fact,

downregulation or loss of E-cadherin during cancer progression is associated with
aggressive behavior of the tumor and poor prognosis [ 1 1 3] . Conversely, expression
of E-cadherin led to a reduced progression and invasion of breast cancer cells
[ 1 1 4] . In this context we will investigate the impact of SMARCAD silencing on
the expression of the metastatic suppressor gene E-cadherin.

3. I mpact of S M A RC AD I silencing o n cell u l a r aggregation : We showed in this

thesis that SMARCAD l -shRNA l and SMARCAD l -shRNA3 cells have stronger
cell-cell adhesion compared to control-shRNA cells. Therefore we would l ike to
investigate the impact of S MARCAD I silencing on the MDA-MB-23 1 adhesive
properties using two assays.
A. Slow aggregation assay: single-cell suspensions will be seeded onto a semi

solid agar medium. After 24 h, aggregate formation will be evaluated subj ectively
by phase-contrast m icroscopy.
B. Fast aggregation assay: single-cell suspensions will be prepared using an E

cadherin saving procedure [ 1 1 5] . Cells will be incubated i n an isotonic buffer
containing 1 .2 5 mM Ca2+ under gyratory shaking for 30 min at 3 7C. Particle
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diameters will be mea ured in a particle size counter (LS 200; Beckman Coulter,
Miami, Fl US) at the start (to) and after 30-min incubation (t30), and plotted
against percentage volume distribution.

4. Abil ity of SMA RC A D I to tran sactivate different su bsets of ta rget gen es to
o rc h estrate cell p ro l iferation a n d colony growth or migration a n d invasion :

This obj ective will be investigated in MDA-MB-23 1 cells transfected with
SMARCAD I -shRNAs (SMARCAD 1 -shRNA 1 & 3) or control sequences (Control
shRNA) using real-time PCR Array of Human Signalling in 3 84-well Plate
containing 380 human genes associated with breast cancer, transcription,
survivaVapoptosis, cell cycle, Epithelial Mesenchymal transition, invasion, cell-cell
adhesion, cell-matrix adhesion, metastasis, DNA replication/repair, and nucleotide
synthesis and 4 assays of endogenous control gene (GAPDH) in a customize array
(Applied Biosystems, US). Genes that are more than two fold up or down regulated
will be analysed using RT-PCR or Western-blot.

5. I mpact of SMA RCA D l silencing o n tumor growth a n d metastasis in nude
mice
A. Tumor growth assay in vivo: S ix-week-old athymic NMRI nude mice

(nulnu, Charles River, Suizfeld, Germany) will be maintained under specified
pathogen-free conditions. Human breast cancer cells MDA-MB-23 1
transfected

with

S MARCAD I -shRNAs

(SMARCAD I -shRNA l ,

stably
and

SMARCA D 1 -shRNA3) or control sequences (Control-shRNA) (5 x 1 06 cells
mixed v/v with matrigel) will be inj ected subcutaneously into the lateral flank of
the mice. Throughout this study, nude mice will be housed in filtered-air laminar
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flow cabinets and manipulated following aseptic conditions. Procedures involving
animals and their care will be conducted in conformity with Institutional guidelines
that are in compliance with col lege of Medicine & Health Sciences national and
international laws and policies (EEC Council Directive 86/609, OJ L 358, 1 ,
December 1 2, 1 987; and

IH Guide for Care and Use of Laboratory Animals, Nlli

Publication No. 85-23 1 985). Tumor dimensions will be measured with calipers
e ery week. Tumor volumes (V) were calculated using the formula: V

=

a x b2 x

0.4, with "a" being the length and "b" the width of the tumor. The animals will be
sacrificed six weeks after cells inj ection and tumors and axil lary lymph nodes will
be exci ed and weighed to determine the impact of SMARCAD 1 silencing on
tumor growth and lymph node metastasis.

B. M etastasis assay in vivo: Six-week-old athymic NMRI nude mIce

(nu/nu, Charles River Suizfeld, Germany) will be maintained under specified
pathogen-free conditions.
transfected

with

Hwnan breast cancer cells M DA-MB-2 3 1

S MARCA D 1 -shRNAs

(SMARCAD 1 -shRNA 1 ,

stably
and

5
SMARCAD 1 -shRNA3) or control sequences (Control-shRNA) ( 1 x 1 0 cells in
1 00�.t1 media) will be injected intravenously into the lateral tail vein of the mice.

Throughout this study, nude mice will be housed in filtered-air laminar flow
cabinets and manipulated following aseptic conditions. Procedures involving
animals and their care will be conducted in conformity w ith Institu tional guidelines
that are in compliance with college of Medicine & Health Sciences, national and
international laws and policies (EEC Council Directive 86/609, OJ L 358, 1 ,
December 1 2, 1 987; and N I H Guide for Care and Use of Laboratory Animals, Nlli
Publication No. 8 5 -2 3 , 1 985). The animals will be sacrificed three months after
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cel ls inj ection and lungs will be excised and weighed to detennine the impact of
SMARCAD 1 si lencing on lung metastasis. These cells are stably transfected with a
vector encoding green fluorescence protein, to allow a rapid and reliable
quantification of micro-metastases in the lungs.
6. I m mu n o histoc hemical exp ression of SMARC A D l in n ormal a n d b reast
cancer tiss ues: We have a total of 58 breast samples of breast carcinomas

fonnalin-fixed paraffm-embedded retrieved from the Department of Pathology
archives that will be used after receiving ethical approval from the Al Ain Medical
District Human Research Ethics Committee. These cases have been previously
studied and characterized for their ER, PR and HER2 status. We also have 4 1
tumor-free tissues from same group of patients. I mmunostaining o f SMARCAD I
will be carried out on deparaffinized sections using the avidin-biotin-peroxidase
complex method. After inhibition of endogenous peroxidases with 3% hydrogen
peroxide, slides will be washed in PBS and incubated w ith 1 0% BSA at room
temperature for 60 minutes. SMARCAD I immunoreactivity will be detected using
a goat polyc1onal antibody directed against the human SMARCAD 1 ( 1 : 50; Santa
Cruz B iotechnology, Santa Cruz, CA) for 2 hours at room temperature in a
humi dified chamber. SMARCAD I

immunohistochemistry specificity will be

checked by omission of primary antibody. All slides will be rinsed three times with
TBS; sections will be incubated with biotinylated secondary antibody ( 1 : 500;
Vector Laboratories, Burlingame, CA) for 60 minutes at room temperature. The
antigen-antibody complex will be revealed with avidin-biotin-peroxidase complex
for 60 minutes according to the manufacturer' s instructions for the Vectastain ABC
kit (Vector Laboratories).

Staining will

done

for

5

minutes w ith 3,3�

diarninobenzidine (Sigma-Aldrich, Lyon, France). All slides will be counterstained
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with hematoxyl in. A semi-quantitative estimation of the number of positive cells
will be done by counting 1 ,000 reactive and nonreactive cells in 1 0 successive
field at the original 1 00 X magnification.
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